CM Management LLC Makes New Investment in enVVeno Medical Corporation $NVNO

CM Management LLC acquired a new position in enVVeno Medical Corporation (NASDAQ:NVNO) in the third quarter, HoldingsChannel reports. The institutional investor acquired 600,000 shares of the company’s stock, valued at approximately $544,000.

Several other institutional investors and hedge funds have also recently modified their holdings of NVNO. Jane Street Group LLC purchased a new position in shares of enVVeno Medical during the 2nd quarter valued at $51,000. Creative Planning purchased a new stake in enVVeno Medical in the 2nd quarter worth $54,000. Geode Capital Management LLC raised its holdings in enVVeno Medical by 1.1% during the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after acquiring an additional 2,211 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of enVVeno Medical in the second quarter valued at about $798,000. Finally, Perceptive Advisors LLC purchased a new position in shares of enVVeno Medical in the second quarter valued at about $5,127,000. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Price Performance

NASDAQ NVNO opened at $11.46 on Friday. enVVeno Medical Corporation has a 1-year low of $8.67 and a 1-year high of $196.70. The business has a 50 day simple moving average of $10.93 and a two-hundred day simple moving average of $18.93. The stock has a market capitalization of $7.56 million, a PE ratio of -0.30 and a beta of 1.12.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

enVVeno Medical Profile

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.